These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16775185)

  • 41. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study.
    Brown DA; Breit SN; Buring J; Fairlie WD; Bauskin AR; Liu T; Ridker PM
    Lancet; 2002 Jun; 359(9324):2159-63. PubMed ID: 12090982
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer.
    Brown DA; Lindmark F; Stattin P; Bälter K; Adami HO; Zheng SL; Xu J; Isaacs WB; Grönberg H; Breit SN; Wiklund FE
    Clin Cancer Res; 2009 Nov; 15(21):6658-64. PubMed ID: 19843661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic markers and the risk of developing prostate cancer.
    Bjartell A
    Eur Urol; 2011 Jul; 60(1):29-31. PubMed ID: 21420228
    [No Abstract]   [Full Text] [Related]  

  • 44. MAG member studies obesity risk factor for aggressive prostate cancer.
    J Med Assoc Ga; 2005; 94(2):40-1. PubMed ID: 16583815
    [No Abstract]   [Full Text] [Related]  

  • 45. Prostate Single Nucleotide Polymorphism Provides a Crucial Clue to Cancer Aggression in Active Surveillance Patients.
    Cooper CS; Clark J; Brewer DS; Edwards DR
    Eur Urol; 2016 Feb; 69(2):229-30. PubMed ID: 26455355
    [No Abstract]   [Full Text] [Related]  

  • 46. Association of Growth and Differentiation Factor 15 in Rheumatoid Arthritis.
    He YW; He CS
    J Inflamm Res; 2022; 15():1173-1181. PubMed ID: 35221707
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia.
    Siddiqui JA; Pothuraju R; Khan P; Sharma G; Muniyan S; Seshacharyulu P; Jain M; Nasser MW; Batra SK
    Cytokine Growth Factor Rev; 2022 Apr; 64():71-83. PubMed ID: 34836750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint.
    Wischhusen J; Melero I; Fridman WH
    Front Immunol; 2020; 11():951. PubMed ID: 32508832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.
    Wang W; Yang X; Dai J; Lu Y; Zhang J; Keller ET
    Oncogene; 2019 Jun; 38(23):4540-4559. PubMed ID: 30755731
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival.
    Freedman JA; Wang Y; Li X; Liu H; Moorman PG; George DJ; Lee NH; Hyslop T; Wei Q; Patierno SR
    Carcinogenesis; 2018 Jul; 39(7):879-888. PubMed ID: 29726910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.
    Amin ARMR; Karpowicz PA; Carey TE; Arbiser J; Nahta R; Chen ZG; Dong JT; Kucuk O; Khan GN; Huang GS; Mi S; Lee HY; Reichrath J; Honoki K; Georgakilas AG; Amedei A; Amin A; Helferich B; Boosani CS; Ciriolo MR; Chen S; Mohammed SI; Azmi AS; Keith WN; Bhakta D; Halicka D; Niccolai E; Fujii H; Aquilano K; Ashraf SS; Nowsheen S; Yang X; Bilsland A; Shin DM
    Semin Cancer Biol; 2015 Dec; 35 Suppl():S55-S77. PubMed ID: 25749195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer.
    Wang X; Baek SJ; Eling TE
    Biochem Pharmacol; 2013 Mar; 85(5):597-606. PubMed ID: 23220538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inherited susceptibility for aggressive prostate cancer.
    Isaacs WB
    Asian J Androl; 2012 May; 14(3):415-8. PubMed ID: 22543676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COX inhibitors directly alter gene expression: role in cancer prevention?
    Wang X; Baek SJ; Eling T
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):641-57. PubMed ID: 22020924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.
    Lin DW; FitzGerald LM; Fu R; Kwon EM; Zheng SL; Kolb S; Wiklund F; Stattin P; Isaacs WB; Xu J; Ostrander EA; Feng Z; Grönberg H; Stanford JL
    Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1928-36. PubMed ID: 21846818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The H6D variant of NAG-1/GDF15 inhibits prostate xenograft growth in vivo.
    Wang X; Chrysovergis K; Bienstock RJ; Shim M; Eling TE
    Prostate; 2012 May; 72(6):677-89. PubMed ID: 21809352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toll-like receptor signaling pathway variants and prostate cancer mortality.
    Stark JR; Wiklund F; Grönberg H; Schumacher F; Sinnott JA; Stampfer MJ; Mucci LA; Kraft P
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1859-63. PubMed ID: 19505919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival.
    Hayes VM; Severi G; Southey MC; Padilla EJ; English DR; Hopper JL; Giles GG; Sutherland RL
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1223-5. PubMed ID: 16775185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer.
    Lindmark F; Zheng SL; Wiklund F; Bensen J; Bälter KA; Chang B; Hedelin M; Clark J; Stattin P; Meyers DA; Adami HO; Isaacs W; Grönberg H; Xu J
    J Natl Cancer Inst; 2004 Aug; 96(16):1248-54. PubMed ID: 15316060
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.